Annals of Surgical Oncology

, Volume 21, Issue 12, pp 3938–3946 | Cite as

The Emerging Role of Neutrophil to Lymphocyte Ratio in Determining Colorectal Cancer Treatment Outcomes: A Systematic Review and Meta-Analysis

  • George Malietzis
  • Marco Giacometti
  • Robin H. Kennedy
  • Thanos Athanasiou
  • Omer Aziz
  • John T. JenkinsEmail author
Colorectal Cancer



There is growing evidence suggesting that the neutrophil to lymphocyte ratio (NLR) can act as an independent predictor of long-term outcomes in patients undergoing treatment for colorectal cancer (CRC). This study aims to systematically review the role of NLR in predicting survival for patients with CRC undergoing treatments, and to evaluate its utility within a CRC surveillance program.


This meta-analysis was performed according to PRISMA guidelines. Outcomes of interest included disease-free survival (DFS) for patients undergoing treatment with curative intent and progression-free survival (PFS) in patients undergoing treatments with palliative intent.


Thirteen observational cohort studies published from 2007 to 2013 evaluated the role of NLR as a predictor of outcome following treatment for CRC. These included (i) patients undergoing surgery to resect the primary cancer (seven studies); (ii) those undergoing palliative chemotherapy (three studies); and (iii) patients undergoing potentially curative treatments for CRC liver metastases (three studies). When all studies were considered, a high pretreatment NLR independently predicted survival (HR 2.08; 95 % CI 1.64–2.64). A high NLR also predicted significantly poorer survival in each of the three groups. Finally, over a 3-year follow-up period, high NLR became a significant predictor of poor outcome at year 2 (HR 2.76; 95 % CI 2.06–3.69; p < 0.00001) and 3 (HR 2.03; 95 % CI 1.48–2.78; p < 0.0001), but not in the first year of follow-up (HR 1.47; 95 % CI 0.89–2.41; p = 0.13).


Elevated preoperative NLR is associated with poorer survival in CRC patients undergoing treatment and may have a role in CRC surveillance programs as a means of delivering more personalized cancer care.


Palliative Chemotherapy Glasgow Prognostic Score Scottish Intercollegiate Guideline Network Neutrophil Lymphocyte Ratio Muscle Mass Depletion 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.




Conflicts of Interest

George Malietzis, Marco Giacometti, Robin H. Kennedy, Thanos Athanasiou, Omer Aziz, and John T. Jenkins declare they have no conflicts of interest.


  1. 1.
    Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454(7203):436–44. doi: 10.1038/nature07205.PubMedCrossRefGoogle Scholar
  2. 2.
    Roxburgh CS, Salmond JM, Horgan PG, Oien KA, McMillan DC. Comparison of the prognostic value of inflammation-based pathologic and biochemical criteria in patients undergoing potentially curative resection for colorectal cancer. Ann Surg. 2009;249(5):788–93. doi: 10.1097/SLA.0b013e3181a3e738.PubMedCrossRefGoogle Scholar
  3. 3.
    McMillan DC. An inflammation-based prognostic score and its role in the nutrition-based management of patients with cancer. Proc Nutr Soc. 2008;67(3):257–62. doi: 10.1017/S0029665108007131.PubMedCrossRefGoogle Scholar
  4. 4.
    McMillan DC. Systemic inflammation, nutritional status and survival in patients with cancer. Curr Opin Clin Nutr Metab Care. 2009;12(3):223–6. doi: 10.1097/MCO.0b013e32832a7902.PubMedCrossRefGoogle Scholar
  5. 5.
    Smith RA, Bosonnet L, Raraty M, et al. Preoperative platelet-lymphocyte ratio is an independent significant prognostic marker in resected pancreatic ductal adenocarcinoma. Am J Surg. 2009;197(4):466–72. doi: 10.1016/j.amjsurg.2007.12.057.PubMedCrossRefGoogle Scholar
  6. 6.
    Walsh SR, Cook EJ, Goulder F, Justin TA, Keeling NJ. Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol. 2005;91(3):181–4. doi: 10.1002/jso.20329.PubMedCrossRefGoogle Scholar
  7. 7.
    Zahorec R. Ratio of neutrophil to lymphocyte counts: rapid and simple parameter of systemic inflammation and stress in critically ill. Bratisl Lek Listy. 2001;102(1):5–14.PubMedGoogle Scholar
  8. 8.
    Guthrie GJK, Charles KA, Roxburgh CS, Horgan PG, McMillan DC, Clarke SJ. The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. Crit Rev Oncol Hematol. 2013;88(1):218–30. doi: 10.1016/j.critrevonc.2013.03.010.PubMedCrossRefGoogle Scholar
  9. 9.
    University of York, Centre for Reviews and Dissemination. Welcome to PROSPERO: international prospective register of systematic reviews. Available from: Accessed 1 Feb 2014.
  10. 10.
    Harbour R, Miller J. A new system for grading recommendations in evidence based guidelines. BMJ. 2001;323(7308):334–6. Available from: Accessed 26 Jun 2013.
  11. 11.
    Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17(24):2815–34. Available from: Accessed 12 Nov 2013.
  12. 12.
    Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16. doi: 10.1186/1745-6215-8-16.PubMedCrossRefPubMedCentralGoogle Scholar
  13. 13.
    Absenger G, Szkandera J, Stotz M, et al. Preoperative neutrophil-to-lymphocyte ratio predicts clinical outcome in patients with stage II and III colon cancer. Anticancer Res. 2013;33(10):4591–4. Available from: Accessed 22 Nov 2013.
  14. 14.
    Zhang Y, Peng Z, Chen M, et al. Elevated neutrophil to lymphocyte ratio might predict poor prognosis for colorectal liver metastasis after percutaneous radiofrequency ablation. Int J Hyperth. 2012;28(2):132–40. doi: 10.3109/02656736.2011.654374.CrossRefGoogle Scholar
  15. 15.
    He W, Yin C, Guo G, et al. Initial neutrophil lymphocyte ratio is superior to platelet lymphocyte ratio as an adverse prognostic and predictive factor in metastatic colorectal cancer. Med Oncol. 2013;30(1):439. doi: 10.1007/s12032-012-0439-x.PubMedCrossRefGoogle Scholar
  16. 16.
    Malietzis G, Giacometti M, Askari A, et al. A preoperative neutrophil to lymphocyte ratio of 3 predicts disease-free survival after curative elective colorectal cancer surgery. Ann Surg. (2013) doi: 10.1097/SLA.0000000000000216.PubMedGoogle Scholar
  17. 17.
    Ding P-R, An X, Zhang R-X, et al. Elevated preoperative neutrophil to lymphocyte ratio predicts risk of recurrence following curative resection for stage IIA colon cancer. Int J Colorectal Dis. 2010;25(12):1427–33. doi: 10.1007/s00384-010-1052-0.PubMedCrossRefGoogle Scholar
  18. 18.
    Kaneko M, Nozawa H, Sasaki K, et al. Elevated neutrophil to lymphocyte ratio predicts poor prognosis in advanced colorectal cancer patients receiving oxaliplatin-based chemotherapy. Oncology. 2012;82(5):261–8. doi: 10.1159/000337228.PubMedCrossRefGoogle Scholar
  19. 19.
    Carruthers R, Tho LM, Brown J, Kakumanu S, McCartney E, McDonald AC. Systemic inflammatory response is a predictor of outcome in patients undergoing preoperative chemoradiation for locally advanced rectal cancer. Colorectal Dis. 2012;14(10):e701–7. doi: 10.1111/j.1463-1318.2012.03147.x.PubMedCrossRefGoogle Scholar
  20. 20.
    Chua W, Charles KA, Baracos VE, Clarke SJ. Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer. Br J Cancer. 2011;104(8):1288–95. doi: 10.1038/bjc.2011.100.PubMedCrossRefPubMedCentralGoogle Scholar
  21. 21.
    Halazun KJ, Aldoori A, Malik HZ, et al. Elevated preoperative neutrophil to lymphocyte ratio predicts survival following hepatic resection for colorectal liver metastases. Eur J Surg Oncol. 2008;34(1):55–60. doi: 10.1016/j.ejso.2007.02.014.PubMedCrossRefGoogle Scholar
  22. 22.
    Hung H-Y, Chen J-S, Yeh CY, et al. Effect of preoperative neutrophil-lymphocyte ratio on the surgical outcomes of stage II colon cancer patients who do not receive adjuvant chemotherapy. Int J Colorectal Dis. 2011;26(8):1059–65. doi: 10.1007/s00384-011-1192-x.PubMedCrossRefGoogle Scholar
  23. 23.
    Mallappa S, Sinha A, Gupta S, Chadwick S. Preoperative neutrophil lymphocyte ratio > five is a prognostic factor for recurrent colorectal cancer. Colorectal Dis. 2013;15(3):323–8. doi: 10.1111/codi.12008.PubMedCrossRefGoogle Scholar
  24. 24.
    Urrejola GI, Bambs CE, Espinoza MA, et al. An elevated neutrophil/lymphocyte ratio is associated with poor prognosis in stage II resected colon cancer [in Spanish]. Rev Med Chil. 2013;141(5):602–8. doi: 10.4067/S0034-98872013000500008.PubMedCrossRefGoogle Scholar
  25. 25.
    Zeman M, Maciejewski A, Półtorak S, Kryj M. Evaluation of outcomes and treatment safety of patients with metastatic colorectal cancer to the liver with estimation of prognostic factors. Pol Przegl Chir. 2013;85(6):333–9. doi: 10.2478/pjs-2013-0050.PubMedGoogle Scholar
  26. 26.
    Li M-X, Liu X-M, Zhang X-F, et al. Prognostic role of neutrophil-to-lymphocyte ratio in colorectal cancer: a systematic review and meta-analysis. Int J Cancer. 2014;134(10):2403–13. doi: 10.1002/ijc.28536.PubMedCrossRefGoogle Scholar
  27. 27.
    Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74. doi: 10.1016/j.cell.2011.02.013.PubMedCrossRefGoogle Scholar
  28. 28.
    Bardou M, Barkun AN, Martel M. Obesity and colorectal cancer. Gut. 2013;62(6):933–47. doi: 10.1136/gutjnl-2013-304701.PubMedCrossRefGoogle Scholar
  29. 29.
    Malietzis G, Johns N, Giacometti M, et al. Myopenia and the systemic inflammatory response in patients with operable colorectal cancer: OP43. Colorectal Dis. 2013;15(Suppl 3):22.Google Scholar
  30. 30.
    Richards CH, Roxburgh CS, MacMillan MT, et al. The relationships between body composition and the systemic inflammatory response in patients with primary operable colorectal cancer. PLoS One. 2012;7(8):e41883. doi: 10.1371/journal.pone.0041883.PubMedCrossRefPubMedCentralGoogle Scholar
  31. 31.
    Sato N, Koeda K, Ikeda K, et al. Randomized study of the benefits of preoperative corticosteroid administration on the postoperative morbidity and cytokine response in patients undergoing surgery for esophageal cancer. Ann Surg. 2002;236(2):184–90. doi: 10.1097/01.SLA.0000022025.67985.53.PubMedCrossRefPubMedCentralGoogle Scholar
  32. 32.
    Schmidt SC, Hamann S, Langrehr JM, et al. Preoperative high-dose steroid administration attenuates the surgical stress response following liver resection: results of a prospective randomized study. J Hepatobiliary Pancreat Surg. 2007;14(5):484–92. doi: 10.1007/s00534-006-1200-7.PubMedCrossRefGoogle Scholar
  33. 33.
    Ramanathan ML, Roxburgh CS, Guthrie GJ, et al. Is perioperative systemic inflammation the result of insufficient cortisol production in patients with colorectal cancer? Ann Surg Oncol. 2013;20(7):2172–9. doi: 10.1245/s10434-013-2943-4.PubMedCrossRefGoogle Scholar
  34. 34.
    Chan AT, Ogino S, Fuchs CS. Aspirin use and survival after diagnosis of colorectal cancer. JAMA. 2009;302(6):649–58. doi: 10.1001/jama.2009.1112.PubMedCrossRefPubMedCentralGoogle Scholar
  35. 35.
    Din FV, Theodoratou E, Farrington SM, et al. Effect of aspirin and NSAIDs on risk and survival from colorectal cancer. Gut. 2010;59(12):1670–9. doi: 10.1136/gut.2009.203000.PubMedCrossRefGoogle Scholar
  36. 36.
    Bastiaannet E, Sampieri K, Dekkers OM, et al. Use of aspirin postdiagnosis improves survival for colon cancer patients. Br J Cancer. 2012;106(9):1564–70. doi: 10.1038/bjc.2012.101.PubMedCrossRefPubMedCentralGoogle Scholar

Copyright information

© Society of Surgical Oncology 2014

Authors and Affiliations

  • George Malietzis
    • 1
    • 2
  • Marco Giacometti
    • 1
  • Robin H. Kennedy
    • 1
    • 2
  • Thanos Athanasiou
    • 2
  • Omer Aziz
    • 1
    • 2
  • John T. Jenkins
    • 1
    • 2
    Email author
  1. 1.Department of SurgerySt. Mark’s HospitalHarrowUK
  2. 2.Department of Surgery and CancerImperial College LondonLondonUK

Personalised recommendations